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While the assiduity of Castleberry et al in compiling and analysing
this huge data assemblage is commendable, regrettably, their
conclusion that population CT screening is more cost-effective
than symptomatic tumour identification at improving lung
cancer (LC) outcomes is based on three demonstrably flawed
premises:
(1) Survival is a valid metric of LC screening efficacy. Efficacy
denotes a reduction in mortality. Although it is counter-
intuitive, increased LC survival has not proven to be a valid
surrogate or proxy for increased life expectancy. Using
SEER data, Welch et al (2000) reported that in 1950–1954 vs
1989–1995, 5-year LC survival more than doubled (from 6 to
14%), while the increase in incidence (249%) was exceeded
by the increase in mortality (259%). Similarly, 5-year LC
survival in the intervention cohorts of the randomised,
prospective, Mayo Lung Program and Czech trials of radio-
graphic screening was more than twice that in the controls.
Nevertheless, their mortality exceeded that of the controls
(Reich, 2002).
(2) Favourable 5-year survival estimates demonstrate the
effectiveness of LC screening. Effectiveness denotes out-
comes in community settings. It presupposes efficacy, the
maximum reduction in mortality attainable in centers of
excellence in which staffs are highly proficient, subjects are
pre-screened to exclude those with clinically significant
morbidities, and the ‘healthy volunteer effect’ obtains. As
these conditions are not uniformly and comprehensively
met in community settings, their outcomes will be predictably
less favourable. Since efficacy of LC screening has not
been demonstrated, estimates of cost-effectiveness are
meaningless.
(3) Overdiagnosis is so infrequent that it can be disregarded.
Overdiagnosis denotes the screen identification of LCs that are
clinically irrelevant, that is, that would not have become
manifest within the individual’s lifetime. On the basis of the
excess number of LCs identified in the intervention cohorts vs
controls in the Mayo Lung Project and Czech screening trials,
I estimated that the radiographic overdiagnosis exceeded 25%
(Reich, 2008). This estimate is conservative, for the computa-
tion assumed that all control cases, many of which were
screen-identified, were clinically relevant. Owing to its
exquisite sensitivity in identifying small, slow-growing
cancers, CT screening overdiagnosis will be quite possibly
twice this figure (Reich, 2008).
Because of its import and its critical contribution to the
controversy surrounding LC screening, the implications of over-
diagnosis deserve elaboration. Although some authors have
insisted on its non-existence, advancing in support the well-
known lethality of clinically identified LC, it is important to
acknowledge that screening identifies a phenotypically less
aggressive LC population. A belief in its invariable lethality entails
the untenable corollary that, however obtained, a diagnosis of LC
confers immunity to death from all other causes. The issue
therefore is quantity. In considering the much-disputed point
about its frequency, the following should be taken into account.
(1) The majority of screen-identified cases are slow-growing
stage I adenocarcinomas, whose natural history permits lengthy
exposure to competing lethal morbidities, which are parti-
cularly common among older smokers. (2) Although volunteers
were selected for participation in trials on the basis of their
high risk for LC combined with their excellent health and ability
to undergo resectional thoracic surgery, competing lethal
morbidities were a far more frequent cause of death than LC.
For example, in the Mayo Lung Project, non-LC deaths (most of
them attributed to coronary artery disease) were sevenfold the
deaths due to LC. (3) Individuals disputing the existence of a
substantial number of overdiagnosed persons point out the high
death rate of persons with stage I LC who decline intervention.
This assumption incorrectly imputes LC as the cause of death
among many persons whose decision, without doubt, reflects their
or their physician’s recognition of manifest lethal comorbidities.
It is a tautological fallacy to ascribe their deaths to previously
diagnosed LC and conclude that stage I LC is therefore invariably
lethal.
Overdiagnosis has two insidious effects. First, it favourably
biases outcome estimates. As overdiagnosed persons, by defini-
tion, die of another cause, their LC survival will be 100% with or
without therapy. Thus, their contribution to outcome improve-
ment as reflected in LC survival is entirely spurious. Second,
overdiagnosed persons experience the psychological harm and the
risks and morbidities of invasive diagnostic procedures and
resectional surgery with no possible offsetting benefit. Further-
more, owing to the loss of pulmonary reserve, the courses of
their smoking-induced cardiopulmonary comorbidities are fore-
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with LC was nearly threefold that in persons with colon or breast
cancer.
Additional considerations: The cost estimates of population
screening are immense. Per 5-year survival, the authors estimate a
cost of 100- to 300-thousand dollars. Even if this enhanced survival
translated into a reduction in mortality, its justification, consider-
ing other health-related obligations and alternative means of
reducing LC mortality, would be open to question. More than 90%
of the positive tests in CT trials are false positive, that is, the
positive predictive value of a positive test is o10%. The emotional
and surgical import of false-positive tests merit emphasis: Wilson
et al (2008), in a CT screening study of 3642 persons, reported that
41% had non-calcified nodules, 95% of which were non-cancerous.
Fifty-four subjects underwent thoracic surgery for LC; half as
many (28) underwent thoracic surgery for benign disorders to
exclude LC.
In summary, the current evidence indicates no benefit and a
high likelihood of harm from mass CT LC screening of the at-risk
population.
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